Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review
- PMID: 24023766
- PMCID: PMC3762823
- DOI: 10.1371/journal.pone.0072714
Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review
Abstract
Objective: Osteoarthritis (OA) is the most common form of arthritis worldwide. Pain and reduced function are the main symptoms in this prevalent disease. There are currently no treatments for OA that modify disease progression; therefore analgesic drugs and joint replacement for larger joints are the standard of care. In light of several recent studies reporting the use of bisphosphonates for OA treatment, our work aimed to evaluate published literature to assess the effectiveness of bisphosphonates in OA treatment.
Methods: Literature databases were searched from inception to the 30th June 2012 for clinical trials of bisphosphonates to treat OA pain. Data was appraised and levels of evidence determined qualitatively using best evidence synthesis from the Cochrane Collaboration. The two largest studies were conducted with risedronate in the treatment of knee OA, for which meta-analyses were performed for pain and functional outcomes.
Results: Our searches found 13/297 eligible studies, which included a total of 3832 participants. The trials recruited participants with OA of the hand (n=1), knee (n=8), knee and spine (n=3), or hip (n=1). Our meta-analysis of the two largest knee studies using risedronate 15 mg showed odds ratios favouring placebo interventions for the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain (1.73), WOMAC function (2.03), and WOMAC stiffness (1.82). However, 8 trials (61.5%) reported that bisphosphonates improve pain assessed by VAS scores and 2 (38.5%) reported significant improvement in WOMAC pain scores compared to control groups.
Conclusions: There is limited evidence that bisphosphonates are effective in the treatment of OA pain. Limitations of the studies we analysed included the differences in duration of bisphosphonate use, the dose and route of administration and the lack of long-term data on OA joint structure modification post-bisphosphonate therapy. Future more targeted studies are required to appreciate the value of bisphosphonates in treating osteoarthritis pain.
Trial registration: PROSPERO Register CRD42012002541.
Conflict of interest statement
Figures
Similar articles
-
Celecoxib for osteoarthritis.Cochrane Database Syst Rev. 2017 May 22;5(5):CD009865. doi: 10.1002/14651858.CD009865.pub2. Cochrane Database Syst Rev. 2017. PMID: 28530031 Free PMC article.
-
Bisphosphonates for breast cancer.Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. doi: 10.1002/14651858.CD003474.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474. doi: 10.1002/14651858.CD003474.pub3. PMID: 16034900 Updated.
-
Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle.Cochrane Database Syst Rev. 2015 Oct 17;2015(10):CD010643. doi: 10.1002/14651858.CD010643.pub2. Cochrane Database Syst Rev. 2015. PMID: 26475434 Free PMC article.
-
Bisphosphonates in multiple myeloma: a network meta-analysis.Cochrane Database Syst Rev. 2012 May 16;(5):CD003188. doi: 10.1002/14651858.CD003188.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2017 Dec 18;12:CD003188. doi: 10.1002/14651858.CD003188.pub4. PMID: 22592688 Updated.
-
Bisphosphonate therapy for osteogenesis imperfecta.Cochrane Database Syst Rev. 2016 Oct 19;10(10):CD005088. doi: 10.1002/14651858.CD005088.pub4. Cochrane Database Syst Rev. 2016. PMID: 27760454 Free PMC article.
Cited by
-
Effect of Osteoporosis Treatments on Osteoarthritis Progression in Postmenopausal Women: A Review of the Literature.Curr Rheumatol Rep. 2024 May;26(5):188-195. doi: 10.1007/s11926-024-01139-8. Epub 2024 Feb 19. Curr Rheumatol Rep. 2024. PMID: 38372871 Free PMC article. Review.
-
Incidence of Total Knee Arthroplasty in Older Females with Knee Osteoarthritis and Osteoporosis Treated with Denosumab Compared with Those Treated Using Bisphosphonates: A Population-Based Cohort Study.Life (Basel). 2024 Dec 23;14(12):1704. doi: 10.3390/life14121704. Life (Basel). 2024. PMID: 39768410 Free PMC article.
-
Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis.Drugs Aging. 2015 Mar;32(3):179-87. doi: 10.1007/s40266-015-0243-3. Drugs Aging. 2015. PMID: 25701074 Free PMC article.
-
Aspiration-assisted bioprinting of the osteochondral interface.Sci Rep. 2020 Aug 4;10(1):13148. doi: 10.1038/s41598-020-69960-6. Sci Rep. 2020. PMID: 32753630 Free PMC article.
-
Bone marrow lesions in osteoarthritis: From basic science to clinical implications.Bone Rep. 2023 Feb 25;18:101667. doi: 10.1016/j.bonr.2023.101667. eCollection 2023 Jun. Bone Rep. 2023. PMID: 36909666 Free PMC article.
References
-
- NICE website (2013) Available: www.nice.org.uk/nicemedia/pdf/CG059FullGuideline.pdf.Accessed 2013 Mar 3.
-
- Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, et al. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333: 1437–1443. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical